General Information

Zymeworks is an innovative, clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Our suite of complementary therapeutic platforms and our fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. These capabilities have resulted in multiple wholly-owned product candidates with the potential to drive superior outcomes in large underserved and unaddressed patient populations, as further described below.

Employees: 135
Founded: 2003
Contact Information
Address Suite 540—1385 West 8th Avenue, Vancouver, BC V6H 3V9
Phone Number (604) 678-1388
Web Address https://www.zymeworks.com
View Prospectus: Zymeworks
Financial Information
Market Cap $324.0mil
Revenues $11.0 mil (last 12 months)
Net Income $-33.8 mil (last 12 months)
IPO Profile
Symbol ZYME
Exchange NYSE
Shares (millions): 4.5
Price range $13.00 - $13.00
Est. $ Volume $58.5 mil
Manager / Joint Managers Citigroup/ Barclays/ Wells Fargo Securities/ Canaccord Genuity
CO-Managers Cormark Securities
Expected To Trade: 4/28/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change